NCT00261105已完成4 期
An Open, Multicenter, Non-comparative, Phase IV Trial of Efficacy and Safety of Ketek(Telithromycin) 800mg
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Sanofi
- 主要终点
- Clinical Outcome (Global Assessment by the participating physicians)
研究概览
简要总结
Primary Objectives:
- The primary objective of the study is to evaluate clinical efficacy i.e. to show that with respect to clinical cure rate, Ketek® (telithromycin) in the treatment of community acquired respiratory tract infections: community acquired pneumonia (CAP), acute bacterial exacerbation of chronic bronchitis (AECB) and acute sinusitis (AS), in outpatients.
Secondary Objectives:
The secondary objectives are to:
- Further assess the efficacy of Ketek® (telithromycin) by considering the rate at which additional antibacterials were prescribed to treat the primary infection; the rate of hospitalisation due to a complication of the primary infection and assessment of bacteriological data, chest X-ray and sinus X-ray if available.
- Evaluate safety of Ketek® (telithromycin) through Adverse Event (AE) and Serious Adverse Event (SAE) reporting
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •General Conditions
- •Outpatients
- •Fulfillment of clinical diagnostic criteria for one of the following indications:
- •Mild to moderate Community Acquired Pneumonia (CAP)
- •Acute bacterial Exacerbation of Chronic Bronchitis (AECB)
- •Acute Sinusitis (AS)
- •The Criteria to be fulfilled are:
- •New onset of at least two of the following:
- •Production of purulent sputum
- •Auscultatory findings compatible with pneumonia, e.g. rales, evidence of pulmonary consolidation
- •Dyspnea or tachypnea
- •Elevated total white blood cell count > 10 000/mm3 or >15% bands regardless of total count
- •Chest X-ray findings supporting a clinical diagnosis of bacterial pneumonia (e.g. new infiltrate)
- •The Criteria to be fulfilled are:
- •Chronic bronchitis defined as cough and excessive sputum production for more than 2 consecutive years and on most days in a 3-month consecutive period.
- •Exacerbation defined by:
- •Increase in sputum purulence, or
- •Increase in sputum volume, or
- •Increase in dyspnea
- •The criteria to be fulfilled are:
- •At least two of the major or one major and two minor factors listed below, for more than one week and less than 4 weeks:
- •Major factors:
- •Facial pressure and/or pain
- •Facial congestion or fullness
- •Nasal obstruction
- •Nasal purulence or postnasal discharge
- •Hyposmia or anosmia
- •Minor factors:
- •Halitosis
- •Dental pain
- •Ear pain, pressure or fullness
排除标准
- •General Conditions
- •Subjects presenting with any of the following will not be included in the study:
- •Treatment required during the study with ergot alkaloid derivatives, pimozide, astemizole, terfenadine, cisapride, simvastatin, atorvastatin and lovastatin, and the oral use of the benzodiazepines midazolam, triazolam and alprazolam.
- •History of congenital or family history of long QT syndrome (if not excluded by ECG) or known acquired QT interval prolongation.
- •Known hypersensitivity to telithromycin or to macrolide antibiotics.
- •Hospital acquired infections (hospitalization for more than 72 hours within 7 days of study entry).
- •Pregnant or breast-feeding women. For the women of childbearing potential it is left to the investigators discretion to establish a lack of pregnancy, e.g. with contraceptive use, menstrual pattern, urinary pregnancy test.
- •Subjects with severely impaired renal function (creatinine clearance <30 ml/min).
- •Subjects that had received anti-bacterials for more than 24 hours within 7 days prior to enrollment in the study, unless the treatment has failed.
- •Subjects receiving medications, including other anti-microbials or anti-cancer drugs, that could interfere with the evaluation.
- •Microbiologically documented infection with a pathogen known prior to inclusion to be resistant to the study medications.
- •Infection, other than the primary infection for which the subject is being included in the study that requires use of other systemic anti-bacterial drug.
- •Splenectomised subjects.
- •Use of Ketek® (telithromycin) or participation in a study using Ketek® (telithromycin) in the previous 30 calendar days.
- •Subjects that have received any investigational drug within 4 weeks of enrollment in the study.
- •No subject will be allowed to enroll in this study more than once.
- •Additional exclusion criteria are:
- •Severe pneumonia defined by any one of the following:
- •Judged as needing Intensive Care Unit admission.
- •Need of parenteral antibiotic treatment (if the attending physician wants to prescribe a parenteral treatment for adherence reasons or local prescription habits this is accepted, provided that the patient does not have a severe pneumonia).
- •Acute respiratory failure or requirement for mechanical ventilation.
- •Altered mental status resulting from the infective process.
- •Resting respiratory rate > 30 breaths/min.
- •Chest X-ray showing increase in opacity by > 50% within 48 hours of current evaluation.
- •Total white blood cell count < 4 000/mm
- •Aspiration pneumonia.
- •Pneumonia suspected to be non-bacterial (due to fungus or viral).
- •Subjects suffering from severe bronchiectasis (production of more than 125 mL of sputum/day), cystic fibrosis, active tuberculosis, pulmonary infarction or embolism, bronchial obstruction, lung cancer or lung metastasis, lung abscess, extra-pulmonary extension (like meningitis, septic arthritis, endocarditis).
- •Additional exclusion criteria are:
- •Need of parenteral antibiotic treatment (if the attending physician wants to prescribe a parenteral treatment for adherence reasons or local prescription habits this is accepted, provided that the patient does not have a severe infection).
- •Acute respiratory failure (respiratory distress, hypercarbia, worsening hypoxemia) or requirement for mechanical ventilation.
- •Severe bronchiectasis, cystic fibrosis, active tuberculosis, pulmonary infarction or embolism, bronchial obstruction, lung cancer or lung metastasis, lung abscess.
- •Additional exclusion criteria are:
- •Need of immediate surgery for the treatment of AS.
- •Chronic sinusitis (symptoms lasting more than 4 weeks).
- •Recurrent sinusitis (4 or more episodes of sinusitis requiring antibiotic therapy in the previous 12 months).
- •Nosocomial acquired sinusitis.
- •Cystic fibrosis, immotile cilia syndrome.
- •Obstructive lesions in nasopharynx (e.g. polyps, tumor).
- •Use of nasal, nasogastric or nasotracheal catheters.
结局指标
主要结局
Clinical Outcome (Global Assessment by the participating physicians)
时间窗: During the Study Conduct
次要结局
- Rate at which additional antibacterials were prescribed to treat the primary infection(During the study conduct)
- Rate of hospitalisation due to a complication of the primary infection(During the study conduct)
- Assessment of chest X-ray and sinus X-ray if available.(During the study conduct)
- Adverse Event (AE) and Serious Adverse Event (SAE) reported(from the inform consent signed up to the end of the study)
研究者
相似试验
Unknown
不适用
Huangqi Guizhi Wuwu Decoction in CKD Stage 2-4 Diabetic NephropathyDiabetic NephropathiesNCT05418465The First Affiliated Hospital of Dalian Medical University100
已完成
3 期
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in Japanese Subjects With PN-dependent Short Bowel Syndrome (SBS)Short Bowel SyndromeNCT02340819Shire11
已完成
不适用
Clinical Efficacy and Safety of Leflunomide in Egyptian Patients With Active Rheumatoid ArthritisActive Rheumatoid ArthritisNCT03599986Eva Pharma398
进行中（未招募）
3 期
Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSDNMOSDNeuromyelitis Optica Spectrum DisordersNCT06724809Alexion Pharmaceuticals, Inc.21
招募中
3 期
Investigate the Efficacy of Chemotherapy in Patients With Positive ctDNA After Surgery and Adjuvant Chemotherapy for a Stage III Colorectal CancerColon or Upper Rectum AdenocarcinomaNCT06197425Centre Hospitalier Universitaire Dijon1,660